ADJUVANT TRIAL OUTCOMES
iDFS: ITT population (primary endpoint)1
Based on the primary analysis, dual anti-HER2 adjuvant therapy with PERJETA + Herceptin® (trastuzumab) + chemotherapy vs placebo + Herceptin + chemotherapy demonstrated a reduction in the risk of recurrence in patients with HER2+ early breast cancer (EBC).*2